公开(公告)号：US20210228607A1

公开(公告)日：2021-07-29

申请号：US17051117

申请日：2019-04-24

Applicant: LEMONEX INC. ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Cheol Hee WON ,  Dal Hee MIN

IPC: A61K31/7036 ,  A61K38/14 ,  A61K31/4706 ,  A61K31/5415 ,  A61K31/536 ,  A61K31/661 ,  A61K31/47 ,  A61K31/496 ,  A61K31/282 ,  A61K31/546 ,  A61K31/7048 ,  A61K38/12 ,  A61P31/14

Abstract: A method for treating a flavivirus infection includes administering to a subject in need thereof a composition which includes at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.

公开(公告)号：US11071739B1

公开(公告)日：2021-07-27

申请号：US17036121

申请日：2020-09-29

Applicant: GENUS LIFESCIENCES INC.

Inventor： Vaishnavi Parikh ,  Suhas Gumaste

IPC: A61K31/5415 ,  A61J1/14 ,  A61K9/00

Abstract: Stable oral liquid compositions including chlorpromazine or a pharmaceutically acceptable salt or solvate of chlorpromazine, and methods of administering the compositions, are disclosed.

公开(公告)号：US20210220474A1

公开(公告)日：2021-07-22

申请号：US17129715

申请日：2020-12-21

Applicant: Heron Therapeutics, Inc.

Inventor： Thomas B. Ottoboni ,  Lee Ann Lynn Girotti

IPC: A61K47/34 ,  A61K31/5415 ,  A61K31/445 ,  A61K31/196 ,  A61K9/127 ,  A61K9/14 ,  A61K9/00 ,  A61K47/12 ,  A61K47/14 ,  A61K31/00 ,  A61K31/167 ,  A61K31/245 ,  A61K47/20

Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

公开(公告)号：US20210213028A1

公开(公告)日：2021-07-15

申请号：US17300136

申请日：2021-03-18

Applicant: ICEUTICA PTY LTD.

Inventor： H. William Bosch

IPC: A61K31/5415 ,  A61K9/14 ,  A61K9/16 ,  A61K9/48 ,  A61K9/00 ,  A61K31/00

Abstract: Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.

公开(公告)号：US20210196726A1

公开(公告)日：2021-07-01

申请号：US17183700

申请日：2021-02-24

Applicant: AXSOME THERAPEUTICS, INC.

Inventor： Herriot Tabuteau

IPC: A61K31/5415 ,  A61K31/4196 ,  A61P25/06 ,  A61K47/40 ,  A61K47/02 ,  A61K33/00 ,  A61K47/69

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US20210186885A1

公开(公告)日：2021-06-24

申请号：US16944639

申请日：2020-07-31

Applicant: POWDER PHARMA COATING INC.

Inventor： Jingxu ZHU ,  Yingliang MA ,  Kwok Yui CHOW ,  Qingliang YANG ,  Yunhan ZHANG ,  Herman C. LAM

IPC: A61K9/50 ,  A61P9/00 ,  A61P11/06 ,  A61P25/08 ,  A61P29/00 ,  A61K9/16 ,  A61K31/4439 ,  A61K31/5415

Abstract: The present disclosure provides powder coating compositions for pharmaceutical pellets which include one or more film forming polymers in powder form present in the composition in a range from about 1 to about 95% w/w. The compositions include one or more plasticizers in powder or liquid form present in the composition in quantity to lower the glass transition temperature of the coating composition to a temperature in a range from about 30 to 100° C. The compositions also include one or more one anti-static agents in powder or liquid form present in the composition in a range from about 0.1 to about 95% w/w as well as one or more flow enhancing agents in powder form present in the composition in a range from about 0.1 to about 25% w/w.

公开(公告)号：US20210177971A1

公开(公告)日：2021-06-17

申请号：US17168016

申请日：2021-02-04

Applicant: AXSOME THERAPEUTICS, INC.

Inventor： Herriot Tabuteau

IPC: A61K47/02 ,  A61K31/5415 ,  A61K31/4439 ,  A61K9/00 ,  A61K47/69 ,  A61K47/40 ,  A61K9/20 ,  C08B37/16 ,  A61K45/06

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US11026954B2

公开(公告)日：2021-06-08

申请号：US16484940

申请日：2018-09-02

Applicant: ASARINA PHARMA AB

Inventor： Torbjörn Bäckström

IPC: A61K31/56 ,  A61K31/36 ,  A61K31/44 ,  A61K31/519 ,  A61K31/504 ,  A61K31/415 ,  A61K31/165 ,  A61K31/55 ,  A61K31/573 ,  A61K31/136 ,  A61K31/138 ,  A61K31/15 ,  A61K31/155 ,  A61K31/343 ,  A61K31/4168 ,  A61K31/451 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5415 ,  A61K31/58

Abstract: The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of Tourette's syndrome, obsessive compulsive disorder and/or gambling disorder, as well as methods for treating said disorders and pharmaceutical compositions for use in treatment of said disorders.

公开(公告)号：US11013805B2

公开(公告)日：2021-05-25

申请号：US17016172

申请日：2020-09-09

Applicant: AXSOME THERAPEUTICS, INC.

Inventor： Herriot Tabuteau

IPC: A61K47/02 ,  A61K31/5415 ,  A61K31/4439 ,  A61K9/00 ,  A61K45/06 ,  A61K47/40 ,  A61K9/20 ,  A61K47/69 ,  C08B37/16

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

公开(公告)号：US20210137938A1

公开(公告)日：2021-05-13

申请号：US17059297

申请日：2019-05-31

Applicant: INSTITUT NATIONAL DE SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO (ARAID) ,  MIGUEL HERNANDEZ UNIVERSITY OF ELCHE ,  FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ARAGON ,  CHONGQING UNIVERSITY ,  INSTITUT JEAN PAOLI & IRENE CALMETES ,  UNIVERSITÉ D'AIX-MARSEILLE ,  UNIVERSITY OF ZARAGOZA ,  INSTITUTO ARAGONES DE CIENCIAS DE LA SALUD - ARAGON INSTITUTE OF HEALTH SCIENCES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  CONSIGLIO NAZIONALE DELLE RICERCHE- NATIONAL RESEARCH COUNCIL ITALY

Inventor： Olga ABIAN FRANCO ,  Patricia SANTOFIMIA ,  Yi XIA ,  Jose Luis NEIRA ,  Bruno RIZZUTI ,  Adrian VELAZQUEZ CAMPOY ,  Ling PENG ,  Juan IOVANNA

IPC: A61K31/5415 ,  A61K45/06 ,  C07D279/28 ,  C07D417/12 ,  A61P35/00

Abstract: The present invention relates to the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer, more particularly pancreatic cancer. The inventors found a novel family compounds of formula (I) able to treat a variety of cancers by inhibiting NUPR1, a stress-inducible 82-amino-acid-long, intrinsically disordered member of the AT-hook family of chromatin proteins. Thus, the present invention relates to a compound of formula (I) for its use in the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer. In particular, the inventors tested compounds of formula (I) on four well characterized primary pancreatic cancer-derived cells 02.063 and LIPC (Basal subtype), Foic8b (derived from a liver metastasis) and HN14 (Classical subtype), as well as on other cellular lines derived from different tumors, i.e. U87 (glioblastoma), A375 and B16 (melanoma), U20S and SaOS (osteosarcoma), HT29, SK-CO-1 and LS174T (colon cancer), HepG2 (hepatocarcinoma), PC3 (prostate) and MDA-MB-231 (breast cancer). The compounds per se are also claimed.